While the use of direct and indirect targeting of MYC in pancreatic cancer is under development53, targeting SE-regulated gene networks such as those like MYC with TPL can lead to the elucidation of novel vulnerabilities, which may be eventually targeted using combinatorial therapeutic strategies. The gene discussed is MYC; the disease is familial pancreatic carcinoma.